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Parathyroid carcinoma is a rare cause of primary hyperpara-
thyroidism, and the efficacy of medical therapy and chemo- and
radiotherapy is poor in recurrent or metastatic disease. We re-
port the first case of PTH immunization in which tumor shrink-
age accompanied hormonal, biochemical, and clinical improve-
ments in a patient with metastatic parathyroid carcinoma.
A 50-yr-old woman with refractory parathyroid carcinoma
and pulmonary metastases was immunized eight times between
February 2001 and December 2003 with bovine and modified
human PTH fragments and intact human PTH, mixed with
Freund’s adjuvant. Total and ionized calcium and PTH levels
were assayed weekly for 6 months and regularly thereafter. Tho-
racic computed tomography scans were performed regularly.
Antibodies to all PTH fragments were detected after two
immunizations. Baseline PTH and total calcium were 213.0
ng/liter and 13.96 mg/dl, respectively, and remained elevated
during the first three immunizations. From the fourth immu-
nization onward, PTH and calcium decreased, and the pa-
tient’s clinical condition improved markedly. PTH and cal-
cium levels have remained controlled for more than 24
months, and the sizes (surface area) of pulmonary metastases
decreased from baseline by 39–71%.
This is the first evidence that PTH immunization not only
can improve clinical, hormonal, and biochemical measures in
parathyroid carcinoma but also has an antitumor effect.
(J Clin Endocrinol Metab 89: 3413–3420, 2004)
PARATHYROID CARCINOMA IS a rare cause of pri-mary hyperparathyroidism, historically accounting for
less than 1% of cases, although more recent studies report a
rate of approximately 5% (1). Parathyroid carcinoma is usu-
ally symptomatic at presentation, often markedly so, and
patients commonly have both active bone and renal disease
at diagnosis (1, 2). Important advances have been made in
understanding the molecular pathology of parathyroid car-
cinoma. Recently it has been shown that both familial (3) and
sporadic (4, 5) forms of parathyroid carcinoma are associated
with various mutations in the HRPT2 gene on chromosome
1q25–1q32 suggesting that HRPT2 acts as a tumor suppressor
gene (6).
Treatment of parathyroid carcinoma is surgical in the first
instance, with the initial aim of achieving a cure by complete
tumor resection (2). Recurrence is common (2, 7) and usually
occurs locally in the neck. Parathyroid carcinoma is slow
growing and metastasizes late, with the most frequent sites
of deposits being the lung (40%), cervical lymph nodes (30%),
and liver (10%) (1). Treatment of recurrent disease relies on
surgical resection of local and distant deposits to palliate
hypercalcemia because the primary cause of mortality is
hormonally driven biochemical disturbance, rather than di-
rect tumor invasion. This approach is combined with fluid
support and loop diuretics to increase renal calcium excre-
tion. Few other treatment options exist for patients for whom
surgery is not possible because parathyroid carcinomas are
not radiosensitive and respond poorly to cytotoxic chemo-
therapy (1, 2). Bisphosphonates, which reduce PTH-induced
osteoclast activity, have beneficial but transitory effects on
calcium levels; however, they have no impact on tumor pro-
gression. Other options include calcitonin, octreotide, gal-
lium, and mithramycin, which are occasionally transiently
effective, although the latter two are of limited use because
they are nephrotoxic (1). Collins et al. (8) successfully used a
calcimimetic compound, cinacalcet, to decrease PTH secre-
tion (via increased parathyroid cell sensitivity) and im-
proved symptoms in an elderly patient with refractory para-
thyroid carcinoma, and recent preliminary reports in six
patients with parathyroid carcinoma demonstrated amelio-
ration of hypercalcemia after cinacalcet treatment (9, 10).
Therapeutic immune targeting of cancer cells is a topic of
growing interest as the mechanisms of antigen presentation,
autoimmunity, and immune tolerance become more clearly
defined. A variety of methods have been used to induce and
augment targeting of antigens expressed by cancer cells.
Previously, Bradwell and Harvey (11) reported the success-
Abbreviations: CT, Computed tomography; IRMA, immunoradio-
metric assay.
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ful treatment of a patient with refractory parathyroid carci-
noma by immunization with fragments of the PTH molecule
to break natural tolerance and induce an antibody reaction
against PTH. This method proved successful in reducing
hypercalcemia and concomitantly improved the patient’s
physical status, but there was no antitumor effect. In the
current study, we report for the first time the long-term
hormonal, biochemical, and antitumor effects of anti-PTH
immunotherapy in a patient with refractory metastatic para-
thyroid cancer.
Patients and Methods
A 50-yr-old female patient was referred to the University Hospital
Center, Lie`ge, in September 2000, suffering from hypercalcemia [total
calcium 14.76 mg/dl (3.69 mmol/liter); normal range 8.6–10.2 mg/dl
(2.15–2.55 mmol/liter)] caused by a metastatic parathyroid carcinoma.
She was originally diagnosed with primary hyperparathyroidism at
another center in 1992 at which time both her total calcium [14.0 mg/dl
(3.5 mmol/liter)] and her PTH (736 ng/liter; normal range 10–55 ng/
liter) were markedly elevated. A right-sided parathyroid mass was
identified during cervical exploration and was excised; histology dem-
onstrated a well-differentiated parathyroid carcinoma with lymph node
involvement and local invasion. Surgery was initially successful, with
the patient experiencing a normalization of PTH levels and hungry bone
syndrome, and she was treated with calcium supplementation and vi-
tamin D. Thereafter the patient was well for approximately 6 yr, after
which time she again developed symptomatic hypercalcemia [total cal-
cium 13.32 mg/dl (3.33 mmol/liter)] and was found to have a PTH of
230 ng/liter. Radiological imaging revealed multiple pleuropulmonary
metastases of less than 1 cm in diameter, and the diagnosis of metastatic
parathyroid carcinoma was confirmed after thorascopic wedge resection
of a metastasis. Radiographs demonstrated cyst formation and osteope-
nia, suggestive of osteitis fibrosa cystica (brown tumors). Initial treat-
ment of the patient included iv rehydration and a loop diuretic (furo-
semide). Over this period the patient also received calcitonin, octreotide,
and pamidronate treatment. Although calcium levels decreased initially,
normalization did not occur, and in September 2000, the patient’s total
calcium was 14.76 mg/dl (3.69 mmol/liter), whereas PTH was 223
ng/liter. A thoracic computed tomography (CT) scan at this time re-
vealed tumor progression, compared with the 1998 CT scans, although
no new metastases were visualized. Chemotherapy and radiotherapy
were discussed, but these were declined by the patient.
The patient’s clinical condition continued to deteriorate due to the
metabolic effects of hypercalcemia. She experienced extreme fatigue,
nausea, and weight loss of 3 kg due to dehydration despite 3 liters/d
fluid intake and treatment with loop diuretics (80 mg/d furosemide).
Against this background of disease progression and the failure of ther-
apy, it was decided to offer the patient immunization against PTH. After
approval of the treatment plan by the ethics committee of the hospital
and the provision of informed written consent, the patient underwent
the first immunization in February 2001.
Anti-PTH immunization
Immunogenic preparations of PTH were generated as described pre-
viously by Bradwell and Harvey (11). Briefly, the peptide sequences
of human and bovine PTH1–34 (bioactive aminoterminal sequence),
PTH33–52, and PTH51–84 were synthesized. Modification of human PTH
fragments involved the insertion of single amino acid substitutions in
each peptide fragment. This was achieved during synthesis of the hu-
man peptides by adding a variety of amino acids at position 2, allowing
a random substitution. The bovine peptides were unmodified. Immu-
nogenicity was increased by synthesizing each of the PTH fragments as
multiantigenic peptides (octamers) on lysine webs, connected to a lysine
core (Alta Biosciences, University of Birmingham, Birmingham, UK).
These immunogens were then mixed with commercially produced
whole human PTH molecules (Peninsula Laboratoires, Europe Ltd., St.
Helens, Merseyside, UK), dialyzed against sterile saline and combined
in a proportion of 40:60 with complete Freund’s adjuvant.
The initial immunization (February 12, 2001, d 1) contained 200 g
human and bovine PTH peptide immunogens and 50 g human intact
PTH. Using a 28-gauge needle, the immunization was administered as
eight individual 30-l intradermal injections across the shoulders/up-
per thorax, upper arms, and upper thighs. Subsequent immunizations
were performed using a similar technique in April 2001 and September
2001. Further 100-l booster immunizations in December 2001, June
2002, and November 2002 contained alum as an adjuvant and were
administered as two 50-l intradermal injections in close proximity to
the cervical lymph nodes. The booster immunizations in March 2003 and
December 2003 again contained complete Freund’s adjuvant and were
administered following the same technique and at the same sites as the
first three immunizations.
Serum calcium and PTH assays
At baseline and during immunization, serum ionized calcium (Nova,
Waltham, MA) and total calcium (Hitachi-Boehringer Mannheim, Indi-
anapolis, IN) were measured on a weekly basis.
Three separate assays were used to measure PTH, two routine assays
and one specialized assay. PTH was assessed weekly for 6 months and
regularly thereafter, using a two-site N-terminal phase assay for intact
PTH [N-tact PTH SP immunoradiometric assay (IRMA) kit, DiaSorin,
Stillwater, MN; standard: PTH1–84; first antibody: polyclonal anti-
PTH39–84; second antibody: polyclonal anti-PTH1–34-
125I;  0.1% cross-
reactivity; normal range: 10–55 ng/liter]. A second, C-terminal/mid-
molecule PTH RIA was also used (C/MM PTH parathyroid hormone
100T RIA kit, The Nichols Institute Diagnostics, San Juan Capistrano,
CA; standard: PTH44–68; antibody: polyclonal anti-PTH44–68; tracer:
PTH44–68-
125I; normal range: 61–315 ng/liter). To verify that a genuine
decrease in PTH concentration was occurring, rather than PTH-antibody
blockade of the assays, a third assay was performed using an acid
dissociation procedure, in which 50l of the patient’s serum was diluted
in 200 l of glycerine/HCl and adjusted to a pH of 2.5 using HCl. After
centrifugation in a Centricon 100 (cut-off at 100,000 rpm), the filtrate was
diluted 1:5 in hypoparathyroid (PTH-free) serum, adjusted to pH 7.4
with 0.1 m NaOH and assayed (Roche Elecsys, Vilvoorde, Belgium).
Anti-PTH antibody identification
A semiquantitative method was used to measure anti-PTH antibod-
ies. Individual 0.1-l volumes of PTH peptide fragments (0.5 mg/ml)
were applied to nitrocellulose membranes and incubated with the pa-
tient’s serum diluted 1:500 in PBS. Sheep antihuman IgGFc antibody,
conjugated to peroxidase (1g/ml) (The Binding Site, Birmingham, UK)
was applied, and binding was visualized after the addition of the chro-
mogenic substrate, 3-amino-9-ethyl-carbazole. The control antibody was
an affinity-purified sheep antibody against an unrelated multiantigenic
peptide, applied at concentrations of 5, 20, 80, 320, and 1280 mg/liter to
the dot-blot under the same conditions as the patient’s serum. The titers
of the patient’s anti-PTH antibodies were determined by comparison
with the control antibody.
Lymphocyte cytokine stimulation test
An enzyme linked immunospot assay for interferon-was performed
to assess cytokine release from peripheral blood T cells after antigen
stimulation to measure specific T cell responses (12). Then 2 105 fresh
peripheral blood mononuclear cells were incubated separately with 4g
each of unmodified and modified multiantigenic PTH peptides used for
immunization (see above), and interferon- production was assessed.
Appropriate negative and positive controls were used including an
irrelevant multiantigenic peptide.
Radiological studies
Serial thoracic spiral CT examinations were performed to assess the
size and extent of the pulmonary metastases over the course of immu-
nizations. A CT scan performed on September 26, 2000 (d 139), ap-
proximately 5 months before the first immunization, was used as a
control. Further thoracic CT scans were performed on d 277, 438, 533,
3414 J Clin Endocrinol Metab, July 2004, 89(7):3413–3420 Betea et al. • Immunotherapy of Parathyroid Carcinoma
634, and 877, respectively. All CT scans were performed on the same
scanner (PQ 5000, Philips, Eindhoven, The Netherlands) and worksta-
tion (Voxel Q Philips) using the same technique (noncontrast, breath-
hold for 20 sec in full inspiration). Each lesion was manually contoured
at the largest diameter and the corresponding surface was electronically
measured. The statistical significance of any changes in the lesion surface
was assessed using Student’s t test.
Results
Calcium and PTH levels
At baseline before immunization, the serum PTH and total
calcium levels were 213.0 ng/liter and 13.96 mg/dl (3.49
mmol/liter), respectively. The hormonal and biochemical
responses to the first three immunizations were modest, with
a sustained reduction in PTH and serum calcium being seen
for the first time after the third immunization. Figures 1 and
2 demonstrate the marked response to the fourth immuni-
zation, with PTH falling from 191.5 ng/liter before immu-
nization to 84.5 ng/liter approximately 1 month thereafter.
Over the same time period, the total calcium concentration
mirrored the PTH response, falling from 12.12 mg/dl (3.03
mmol/liter) to within the normal range [9.48 mg/dl (2.37
mmol/liter)]. Both PTH and calcium were normal at the time
of the fifth immunization. Ionized and total calcium normal-
ized first (d 334), followed by PTH (d 365). PTH remained
within the normal range or just above the upper limit of
normal thereafter. Both ionized and total calcium remained
normal for more than 24 months of follow-up, at which time
(February 2004) the patient developed mild hypocalcemia
with total and ionized calcium concentrations of 8.32 mg/dl
(2.08 mmol/liter) and 3.88 mg/dl (0.97 mmol/liter), respec-
tively; PTH was 48.8 ng/liter.
Given the potential for false-low levels of PTH being re-
ported due to masking of the immunoassay by circulating
anti-PTH antibodies, two alternative assays were used. As
shown in Fig. 2, A and B, RIA measurements confirmed the
decrease in PTH levels demonstrated by the IRMA assay. No
excess free PTH was noted after acid dialysis, indicating that
no circulating PTH was being shielded by antibody binding.
Other measures of calcium metabolism were also assessed.
Serum 1, 25-dihydroxyvitamin D concentration was 65.5
ng/ml (normal range: 3–48 ng/ml) at baseline when the
corresponding PTH was 213 pg/ml. When PTH fell to 82.4,
the serum 1, 25-dihydroxyvitamin D normalized at 13.1 ng/
ml. Subsequently the serum 1, 25-dihydroxyvitamin D re-
mained in the range 20 to 55 ng/ml over the series of im-
munizations. Decreased total alkaline phosphatase was also
noted. Total alkaline phosphatase was 753 IU/liter (normal
range 34–117 IU/liter) when the concomitant PTH was 209.5
ng/liter and total calcium was 3.05 mmol/liter. As PTH and
total calcium fell to 2.59 mmol/liter and 55.2 ng/ml, respec-
tively, alkaline phosphatase normalized to 70 IU/liter, and
remained normal thereafter.
Anti-PTH antibody identification
Semiquantitative dot-blot analyses demonstrated that an-
tibodies against the human PTH33–52 and PTH51–84, and the
bovine PTH51–84 fragments were present 3 wk after the first
immunization. From 2 wk after the second immunization
FIG. 1. Evolution of ionized and total calcium levels in a
patient with metastatic parathyroid carcinoma after anti-
PTH immunization. The arrows indicate the date of each
immunization, and the normal ranges for total and ionized
calcium are outlined in gray. Normal range for ionized cal-
cium: 1.13–1.3 mmol/liter; total calcium: 2.15–2.5 mmol/
liter. To convert micromoles per liter to nanograms per
liter, divide by 0.25.
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onward, antibodies against all human and bovine immuno-
gens were identified.
Lymphocyte cytokine stimulation
The enzyme linked immunospot assay showed an antigen-
specific response against the three fragments of unmodified
and modified PTH with a slightly greater response against
the C-terminal peptide. Incubation of the peptides with the
patient’s cells gave a median response of 4 cells/10,000
(range 1–7). This increased to a median response of 7 cells/
10,000 (range 1–12) when the peptides were incubated with
the patient’s serum. Responses using an unrelated control
peptide were 0–1 cells/10,000.
FIG. 2. PTH concentrations during the treatment period, measured using a C-terminal/midmolecule PTH RIA (normal range: 61–315 ng/liter,
A) and a two-site N-terminal phase assay for intact PTH, IRMA (normal range: 10–55 ng/liter, B).
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Radiological response
The mean axial surface of the pulmonary metastases
increased slightly from the baseline CT scan on d 139 to
the scan performed on d 277 after the first immunization.
The last CT scan performed at d 877 revealed a total
decrease of 39.2–71.4% in the size of the pulmonary me-
tastases, which was statistically significant (P 0.05) (Figs.
3 and 4). No additional metastatic pulmonary lesions de-
veloped during treatment. Radiological studies of the skel-
etal lesions showed no progression over the course of
treatment and follow-up.
Clinical status
After the fourth immunization, the patient’s clinical con-
dition improved markedly. A dramatic improvement in the
severity of asthenia, nausea, and muscle weakness was
noted. Over the next 3 months, her appetite returned to
normal and she gained 10 kg. The patient’s fluid intake was
2 liters daily and furosemide was stopped. The patient be-
came more dynamic and her clinical status normalized.
Adverse events
After each immunization the patient developed 5-mm firm
nodules at the injections sites accompanied by local lymph-
adenopathy. Superficial ulceration of nodules occurred but
healed spontaneously to leave small scars. Approximately
10 h after the second immunization, the patient developed a
24-h episode of fever and chills. This was considered retro-
spectively to be due to an immune reaction arising from
PTH/antibody complexes. Apart from anti-PTH antibodies,
no evidence was found of autoantibodies being raised
against other self-antigens (smooth muscle, skin, liver, and
FIG. 3. Axial CT scans showing shrinkage of pulmonary metastases. Shrinkage of the pulmonary metastasis in the left VI segment (arrow)
is shown in scans performed on d 277 (A) and d 877 (B), while a pulmonary metastasis in the left VIII lung segment (arrow) also shrank in
size between the d 277 (C) and d 877 (D) CT scans. The same magnification was used for each image. CT technology at the time of the initial
scan did not permit volume assessment due to anisotropism in the z-axis. Therefore, surface measurements underestimate the actual volume
reduction.
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stomach), and no antinuclear antibodies were identified dur-
ing the follow-up period.
Discussion
Neuroendocrine tumors are often indolent in character
and tend to produce symptoms through hormonal secretion
rather than by tumor invasion. In metastatic parathyroid
carcinoma, the main problems stem from the uncontrolled
effects of excess PTH, and the main causes of morbidity and
mortality are hypercalcemia and bone disease. Treatment
options for refractory and metastatic disease are limited be-
cause parathyroid carcinoma is largely unresponsive to
chemo- and radiotherapy. Therefore, novel therapeutic reg-
imens that limit the actions of PTH in parathyroid carcinoma
are of interest.
Previous experience has shown that it is possible to reduce
hypercalcemia by blocking the effects of high PTH concen-
trations with neutralizing antibodies. In 1999, Bradwell and
Harvey (11) attempted to control severe, intractable hyper-
calcemia in a patient with terminal parathyroid carcinoma by
inducing autoantibody formation to human PTH. This in-
volved breaking normal immune tolerance to PTH by using
human and bovine PTH-like immunogenic fragments to
stimulate the production of an antibody that would cross-
react with human PTH. Whereas this immunologic response
was achieved and a reduction in serum calcium occurred,
that patient had established severe bone disease and died
from complications after the fracture of a femoral bone cyst.
One particular feature in that patient had been the rising
concentrations of serum PTH because the blocking antibod-
ies formed immune complexes and extended its normal se-
rum half-life. In our patient the high initial PTH and calcium
concentrations normalized with repeated immunizations
over a 9- to 12-month period. To rule out any interference by
induced antibodies with PTH measurements, both a two-site,
N-terminal phase assay for intact PTH and a C-terminal/
midmolecule assay were used. Although both assays were in
agreement, further proof of the reduced PTH concentrations
was sought. PTH was separated from potentially binding
antibodies by acid dialysis and reanalyzed, but serum PTH
concentrations indicated that no shielding of PTH by circu-
lating antibodies had occurred.
In parallel with these observations, axial CT scans of the
lung metastases showed dramatic reductions in size. This
provided an explanation for the reduced PTH concentrations
and was a welcome but unexpected finding, particularly
because no tumor regression had been seen in the previous
case. There are more than 600 patients recorded with para-
thyroid carcinoma since 1937 (1, 2), and to our knowledge
spontaneous tumor regression has not been reported in the
literature. It appears, therefore, that immunotherapy may
have not only stimulated antibodies against PTH but also
substantially reduced tumor mass because tumor shrinkage
is not a natural feature of the disease.
We chose a combination of human, modified human and
bovine peptides for immunotherapy. Modified human pep-
tides were added to peptides used in the initial immuniza-
tion protocols but were eventually used alone. The human
peptides contained single amino acid substitutions at posi-
tion 2 of each fragment and were more similar to human
molecules than their bovine counterparts. Thus, satisfactory
major histocompatability complex presentation of antigens
from B cells to T cells was encouraged, while maintaining
minimal structural differences to favor cross-recognition of
human proteins. These peptides have been used in two other
patients with good initial responses and appeared more ef-
fective than unmodified bovine and human peptides (13).
We used Freund’s complete adjuvant because of its high
potency for inducing antibodies, but it is equally a very
effective agent for inducing cellular immune responses. It is
safe to use, although uncomfortable for the patient, and side
effects can be minimized with careful intradermal injections.
The progress of immunotherapy was monitored using an
antibody dot-blot assay. Immune responses to each of the
PTH component fragments were assessed on a weekly basis,
and subsequent immunizations were modified to increase
the amounts of peptides that had weak antibody responses.
By targeting three separate portions of the molecule, anti-
FIG. 4. Evolution of the dimensions (square mil-
limeters) of five pulmonary metastases during
the course of PTH immunizations. Data are
shown in terms of surface areas.
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bodies were produced against several parts of the whole
human PTH molecule, thus promoting the development of
large, circulating PTH-antibody immune complexes, which
could be removed by Fc receptor-bearing cells.
Immunotherapy of solid tumors has generally been inef-
fective for reasons that are not yet wholly clear. The use of
whole tumor cell extracts and cell lysates may be inappro-
priate because of the plethora of antigens in the vaccines.
Many of these are not specific to the tumor, whereas those
that are tumor specific may be present in low, nonimmuno-
genic concentrations. Dendritic cells, pulsed with patient’s
tumor extracts in vitro, have been used in parathyroid and
other carcinomas but again with poor results (14–17), pos-
sibly related to inadequate antigen processing. Furthermore,
the use of strong adjuvants to break tolerance has been
avoided in many studies because of anxieties about toxicity.
There are a number of potential mechanisms by which
immunotherapy could have caused tumor regression in this
patient. The induced antibodies would naturally accumulate
at the site of the highest concentrations of PTH, adjacent to
PTH-producing parathyroid carcinoma cells. Potentially,
this may have induced immune activation, leading to tumor
cell destruction or the induction of apoptosis. This mecha-
nism was supported by the observation of considerable pe-
ripheral blood mononuclear cell responses to the immunized
peptides and human PTH. Because the lymphocyte stimu-
lation test for PTH-reacting cells showed a higher level of
response to PTH than to a control peptide, this may indicate
the recruitment of cytotoxic T cells against the immunogen,
which could be responsible for the observed antitumor effect.
Studies of tumor responses to immunotherapy in melanoma
show similar findings, although patients may have good
responses but no evidence of tumor regression and vice versa
(18). It was recently shown that T cell infiltration of tumors
was an important indicator of outcome in ovarian (19) and
other tumors (20). Biopsy assessment of the tumor in our
patient would have been helpful in ascertaining the antitu-
mor mechanism; however, a lung biopsy to evaluate this
possibility was considered clinically inappropriate. Other
antitumor mechanisms can be speculated upon. PTH may act
as a growth factor for parathyroid carcinoma cells because it
activates important signal transduction pathways in vitro (21,
22). Hyperparathyroidism and hypercalcemia are associated
with a variety of alterations in normal cellular immune func-
tion and cytokine production (23–25). Thus, the reduction in
PTH may have improved immune targeting of the carcinoma
cells by cytotoxic T lymphocytes.
Similar immunotherapy in other patients with parathyroid
carcinoma needs to be considered both in terms of the pos-
sibility of success and the risk/benefit ratio. Our patient was
relatively young and was expected to live several months,
which was sufficient time for a good immune response. She
had not had chemotherapy, irradiation to the neck, cervical
lymph node removal, or thymectomy, and she was not on
corticosteroids, all of which were favorable for immunother-
apy. Further surgical intervention carried a low probability
of success, and chemotherapy was declined. Whereas the risk
of immunotherapy cannot be quantified in the limited num-
ber of patients treated so far, the satisfactory outcome and
benign side effects suggest that it should be considered be-
fore patients are terminally ill. It might also be considered
before the use of treatments that destroy cervical lymphoid
tissues, including repeated cervical surgery.
In conclusion, this is the first case of successful immuni-
zation against PTH in a patient with parathyroid carcinoma,
in which hormonal and biochemical normalization was ac-
companied by tumor regression. The patient has been well
for more than 24 months; however, it is still too early for
long-term predictions because parathyroid carcinomas are
very slow growing. It remains to be seen whether tumor
regression can be achieved in other patients, but the findings
in this case confirm that PTH immunization represents a
potentially effective therapy for patients with refractory
parathyroid carcinoma.
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